Amila Rathnapala

Job Title
Consultant Respiratory Physician
Faculty / Department / Division
Respiratory Medicine
Institution / Organisation
National Hospital Galle

19 November 2026, Thursday

Time Session
08:30
13:00
Naricha Chirakalwasan Chairperson Thailand
Rashidah Yasin Chairperson Malaysia
Function Room 8, Ground Mezzanine Floor

20 November 2026, Friday

Time Session
09:30
11:00
Moo Suk Park Chairperson Republic of Korea
Noorul Afidza Muhammad Chairperson Malaysia
  • Ganesh Raghu Speaker United States
  • Jin Woo Song Speaker Republic of Korea
    Interstitial lung abnormalities (ILAs) are chest CT findings suggestive of interstitial lung disease (ILD) in people without a clinical diagnosis of ILD. With lung cancer screening and the wide use of CT, they are increasingly encountered in respiratory practice. The 2025 American Thoracic Society (ATS) clinical statement updated the 2020 Fleischner Society definition: ILA is now defined as bilateral, nondependent ground-glass or reticular abnormalities, lung distortion, traction bronchiectasis, or honeycombing involving at least 5% of a lung zone, without the requirement that the findings be incidental, and with high-risk groups such as familial pulmonary fibrosis and connective tissue disease included. A working definition separates ILA from ILD on the basis of symptoms, physiology, imaging, and pathology. ILA is found in about 3–10% of older adults and 4–17% of smokers. Risk factors include older age, male sex, smoking, occupational and environmental exposures, the MUC5B promoter variant, short telomeres, and a family history of pulmonary fibrosis. ILA is associated with respiratory symptoms, reduced exercise capacity, lung cancer, complications of cancer treatment and surgery, acute respiratory distress syndrome, and all-cause mortality. About half of ILAs progress radiologically, and subpleural fibrotic ILA, reticulation, and traction bronchiectasis carry the highest risk of progression and death. Based on 11 questions, the ATS statement suggests systematic assessment of ILA on lung cancer screening CT, baseline CT for adults with connective tissue disease at risk of ILD and for first-degree relatives older than 50 years in familial pulmonary fibrosis, assessment of symptoms and lung function at baseline, and serial CT timed by risk; it suggests against lung biopsy and routine MUC5B or telomere testing. Risk reduction, including smoking cessation and exposure remediation, is recommended throughout. No pharmacological treatment is currently recommended for ILA, but prevention trials with better-tolerated antifibrotics, such as DROP-FPF with nerandomilast, have begun. This lecture reviews the definition, epidemiology, clinical significance, risk assessment, and management of ILA, with data from Korean cohorts.
  • Yasuhiko Nishioka Speaker Japan
  • Q&A
Ballroom 4, Lower Ground Floor
12:00
13:00
Sponsored by Orient EuroPharma
Mat Zuki Bin Mat Jaeb Chairperson Malaysia
Ballroom 1, Lower Ground Floor
15:00
16:00

21 November 2026, Saturday

Time Session
09:30
10:30
11:00
12:30
Chai Chan Sin Chairperson Malaysia
Fatimah Azmah Mohammad Chairperson Malaysia
  • Parth Rali Speaker United States
  • Luis Jara-Palomares Speaker Spain
    Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially treatable cause of pulmonary hypertension characterised by persistent organised pulmonary arterial obstruction and secondary microvascular remodelling. Despite advances in management, delayed recognition and unequal access to expert care remain important challenges. This presentation reviews the contemporary diagnostic and therapeutic pathway, integrating guideline recommendations with evidence from clinical trials and international registries. Persistent dyspnoea or exercise limitation after pulmonary embolism should prompt structured assessment, while the absence of a recognised embolic event does not exclude CTEPH. Ventilation–perfusion imaging, anatomical assessment and right heart catheterisation provide complementary information for diagnosis and treatment planning. Multidisciplinary evaluation is central to selecting pulmonary endarterectomy, balloon pulmonary angioplasty and medical therapy. Lifelong therapeutic anticoagulation remains essential, although uncertainty persists regarding the optimal anticoagulant for patients without antiphospholipid syndrome. Symptomatic chronic thromboembolic pulmonary disease without resting pulmonary hypertension requires careful symptom attribution and individualised treatment decisions. Future developments include circulating biomarkers, novel therapies targeting vascular remodelling and artificial intelligence for earlier detection, complication prediction and phenotyping. Multimodal models integrating clinical, biochemical and imaging data could support diagnostic testing and referral decisions, but require external validation and prospective demonstration of clinical benefit. Earlier recognition, timely expert referral and individualised multimodal care remain the priorities for improving outcomes.
  • Q&A
Ballroom 3, Lower Ground Floor
12:30
13:30
14:00
15:30
Amila Rathnapala Chairperson Sri Lanka
Gin Tsen Chai Chairperson Singapore
  • Marissa O'Callaghan Speaker Ireland
    Pulmonary alveolar proteinosis (PAP) is a rare but treatable cause of respiratory impairment that presents important diagnostic and therapeutic challenges. Using a case-based approach, this presentation will explore when to suspect PAP, how to confirm the diagnosis and distinguish its underlying causes, and when to consider treatment. It will highlight the roles of bronchoalveolar lavage and GM-CSF autoantibody testing, alongside practical approaches to assessing disease severity and progression. Established and emerging treatments, including whole-lung lavage and inhaled GM-CSF, will be discussed. Attendees will gain a practical framework for recognising PAP, initiating appropriate investigations and identifying patients who would benefit from specialist referral.
  • Moo Suk Park Speaker Republic of Korea
  • Q&A
Ballroom 3, Lower Ground Floor